Respiratory syncytial virus: prospects for new and emerging therapeutics

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

(2017) Dustin Siegel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nanobodies® † †Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases

(2017) Gino Van Heeke et al.   PHARMACOLOGY & THERAPEUTICS

Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus

(2017) Stephanie McCallum Blake et al.   Advances in Neonatal Care

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

(2016) M. Pamela Griffin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses

(2016) Jennifer L. McKimm-Breschkin et al.   ANTIVIRAL RESEARCH

New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase

(2016) Rachel Fearns et al.   ANTIVIRAL RESEARCH

Taxonomy of the order Mononegavirales: update 2016

(2016) Claudio L. Afonso et al.   ARCHIVES OF VIROLOGY

Structure-guided design of small-molecule therapeutics against RSV disease

(2016) Robert Cox et al.   Expert Opinion on Drug Discovery

Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development

(2016) José A. Melero   Expert Review of Vaccines

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

(2016) Jens Gottlieb et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

(2016) Travis K. Warren et al.   NATURE

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV

(2016) M Gordon Joyce et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop

(2016) Jeffrey N. Roberts et al.   VACCINE

Advances in RSV vaccine research and development – A global agenda

(2016) Deborah Higgins et al.   VACCINE

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV

(2016) M Gordon Joyce et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Determinants of early life immune responses to RSV infection

(2016) Tracy J Ruckwardt et al.   Current Opinion in Virology

Anti-Viral Activities of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-Protein Polymerase

(2016) Kazuhiro Ito et al.   Open Forum Infectious Diseases

Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus

(2016) Jeffrey C. Boyington et al.   PLoS One

GS-5806 Inhibits Pre- to Postfusion Conformational Changes of the Respiratory Syncytial Virus Fusion Protein

(2015) Dharmaraj Samuel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process

(2015) Michel Perron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

(2015) Laurent Detalle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: Identification of BTA9881 as a preclinical candidate

(2015) Silas Bond et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1

(2015) Silas Bond et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

(2015) Patricia A. Jorquera et al.   Expert Review of Vaccines

Chemotherapy of respiratory syncytial virus infections: the final breakthrough

(2015) Erik De Clercq   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics

(2015) E. A. F. Simoes et al.   JOURNAL OF INFECTIOUS DISEASES

Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter

(2015) Sarah L. Noton et al.   JOURNAL OF VIROLOGY

A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus

(2015) Mohamed Ouizougun-Oubari et al.   JOURNAL OF VIROLOGY

New Host Factors Important for Respiratory Syncytial Virus (RSV) Replication Revealed by a Novel Microfluidics Screen for Interactors of Matrix (M) Protein

(2015) Sarit Kipper et al.   MOLECULAR & CELLULAR PROTEOMICS

Molecular mechanism of respiratory syncytial virus fusion inhibitors

(2015) Michael B Battles et al.   Nature Chemical Biology

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

(2015) John P. DeVincenzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering and expression of a RhoA peptide against respiratory syncytial virus infection in plants

(2015) Benita Ortega-Berlanga et al.   PLANTA

A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus

(2015) Guillaume B. E. Stewart-Jones et al.   PLoS One

Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein

(2015) Jason S McLellan   Current Opinion in Virology

Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures

(2015) Sara M. Johnson et al.   PLoS Pathogens

Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention

(2015) Haben Y Abraha et al.   Expert Review of Respiratory Medicine

Phase 1 Study Evaluating Safety, Tolerability, Pharmacokinetics and Immunogenicity of REGN2222 in Healthy Adults: A New Human Monoclonal RSV-F Antibody for RSV Prevention

(2015) Sumathi Sivapalasingam et al.   Open Forum Infectious Diseases

Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604

(2014) SreeRupa Challa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis

(2014) Anne L. Hotard et al.   JOURNAL OF VIROLOGY

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children

(2014) Christopher S Ambrose et al.   Human Vaccines & Immunotherapeutics

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants

(2014) Michael L Forbes et al.   Human Vaccines & Immunotherapeutics

Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor

(2013) Hui Xiong et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

(2013) Marcello Lanari et al.   Clinical & Developmental Immunology

A Novel Influenza Virus Hemagglutinin-Respiratory Syncytial Virus (RSV) Fusion Protein Subunit Vaccine against Influenza and RSV

(2013) T. M. Turner et al.   JOURNAL OF VIROLOGY

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

(2013) J. S. McLellan et al.   SCIENCE

Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein

(2013) Zhiwu Sun et al.   Viruses-Basel

Prophylaxis and Treatment of Respiratory Syncytial Virus in Adult Immunocompromised Patients

(2012) Lauren M Hynicka et al.   ANNALS OF PHARMACOTHERAPY

Inhibition of Human Respiratory Syncytial Virus Infectivity by a Dendrimeric Heparan Sulfate-Binding Peptide

(2012) Manuela Donalisio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

(2011) J. S. McLellan et al.   JOURNAL OF VIROLOGY

Identification of nucleolin as a cellular receptor for human respiratory syncytial virus

(2011) Farnoosh Tayyari et al.   NATURE MEDICINE

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

(2011) Peter L. Collins et al.   VIRUS RESEARCH

RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus

(2010) Martin R. Zamora et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Surfactant proteins and respiratory syncytial virus

(2010) Mika Rämet et al.   JOURNAL OF PEDIATRICS

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

(2010) K. Huang et al.   JOURNAL OF VIROLOGY

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

(2010) Harish Nair et al.   LANCET

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

(2010) J. DeVincenzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy

(2009) R. Alvarez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY